Discovery of the First N-Substituted 4β -Methyl-5-(3-hydroxyphenyl)morphan to Possess Highly Potent and Selective Opioid δ Receptor Antagonist Activity

Journal of Medicinal Chemistry

Volumn 47, Issue 2, 2004, Pages 281-284

  Carroll, F Ivy ^a   Zhang, Li ^a   Mascarella, S Wayne ^a   Navarro, Hernán A ^a   Rothman, Richard B ^c   Cantrell, Buddy E ^b   Zimmerman, Dennis M ^b   Thomas, James B ^a  

^a RTI INTERNATIONAL   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4BETA METHYL 5 (3 HYDROXYPHENYL)MORPHAN; 5 (3 HYDROXYPHENYL) 4 METHYL 2 (3 PHENYLPROPYL) 2 AZABICYCLO[3.3.1]NON 7 YL (1 PHENYL 1 CYCLOPENTANE)CARBOXAMIDE; DELTA OPIATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; HUMANS; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, DELTA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0346962973     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030419a     Document Type: Article

References (33)

1. Dhawan, B. N.; Cesselin, F.; Raghubir, R.; Reisine, T.; Bradley, P. B.; Portoghese, P. S.; Hamon, M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 1996, 48, 567-592.
2. Matthes, H. W.; Maldonado, R.; Simonin, F.; Valverde, O.; Slowe, S.; Kitchen, I.; Befort, K.; Dierich, A.; Le Meur, M.; Dolle, P.; Tzavara, E.; Hanoune, J.; Roques, B. P.; Kieffer, B. L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383, 819-23.
3. Carroll, F. I. 2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy. J. Med. Chem. 2003, 46, 1775-1794.
4. Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ opioid agonists and antagonists. Expert Opin. Ther. Pat. 1997, 7, 1075-1098.
5. Bilsky, E. J.; Calderon, S. N.; Wang, T.; Bernstein, R. N.; Davis, P.; Hruby, V. J.; McNutt, R. W.; Rothman, R. B.; Rice, K. C.; Porreca, F. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J. Pharmacol. Exp. Ther. 1995, 273, 359-366.
6. Tseng, L. F.; Narita, M.; Mizoguchi, H.; Kawai, K.; Mizusuna, A.; Kamei, J.; Suzuki, T.; Nagase, H. Delta-1 opioid receptor-mediated antinociceptive properties of a nonpeptidic delta opioid receptor agonist, (-)TAN-67, in the mouse spinal cord. J. Pharmacol. Exp. Ther. 1997, 280, 600-605.
7. Cheng, P. Y.; Wu, D.; Decena, J.; Soong, Y.; McCabe, S.; Szeto, H. H. Opioid-induced stimulation of fetal respiratory activity by [D-Ala2]deltorphin I. Eur. J. Pharmacol. 1993, 230, 85-88.
8. Schmidhammer, H. Opioid receptor antagonists. Prog. Med. Chem. 1998, 35, 83-132.
9. Henry, B.; Fox, S. H.; Crossman, A. R.; Brotchie, J. M. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 2001, 171, 139-146.
10. June, H. L.; McCane, S. R.; Zink, R. W.; Portoghese, P. S.; Li, T. K.; Froehlich, J. C. The delta 2-opioid receptor antagonist naltriben reduces motivated responding for ethanol. Psychopharmacology (Berl.) 1999, 147, 81-89.
11. Kamei, J. Delta-opioid receptor antagonists as a new concept for central acting antitussive drugs. Pulm. Pharmacol. Ther. 2002, 15, 235-240.
12. Maneckjee, R.; Biswas, R.; Vonderhaar, B. K. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res. 1990, 50, 2234-2238.
13. Maneckjee, R.; Minna, J. D. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 3294-3298.
14. Campa, M. J.; Schreiber, G.; Bepler, G.; Bishop, M. J.; McNutt, R. W.; Chang, K. J.; Patz, E. F., Jr. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res. 1996, 56, 1695-1701.
15. Schwyzer, R. ACTH: A short introductory review. Ann. N. Y. Acad. Sci. 1977, 247, 3-26.
16. Takemori, A. E.; Sofuoglu, M.; Sultana, M.; Nagase, H.; Portoghese, P. S. In New Leads in Opioid Research; van Reed, J. M., Mulder, A. H., Wiegant, V. M., van Wimersma Greidanus, T. B. Eds.; Elsevier: Amsterdam, 1990; p 277.
17. Takemori, A. E.; Sultana, M.; Nagase, H.; Portoghese, P. S. Agonist and antagonist activities of ligands derived from naltrexone and oxymorphone. Life Sci. 1992, 50, 1491-1495.
18. McLamore, S.; Ullrich, T.; Rothman, R. B.; Xu, H.; Dersch, C.; Coop, A.; Davis, P.; Porreca, F.; Jacobson, A. E.; Rice, K. C. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5α-epoxy-3,14-dihydroxy-6,7:2′, 3′-indolom orphinans, on opioid receptor affinity, selectivity, and efficacy. J. Med. Chem. 2001, 44, 1471-1474.
19. Dondio, G.; Ronzoni, S.; Petrillo, P. Non-peptide δ opioid agonists and antagonists (Part II). Expert Opin. Ther. Pat. 1999, 9, 353-374.
20. Thomas, J. B.; Atkinson, R. N.; Namdev, N.; Rothman, R. B.; Gigstad, K. M.; Fix, S. E.; Mascarella, S. W.; Burgess, J. P.; Vinson, N. A.; Xu, H.; Dersch, C. M.; Cantrell, B. E.; Zimmerman, D. M.; Carroll, F. I. Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4β-methyl-5-(3-hydroxyphenyl)morphans. J. Med. Chem. 2002, 45, 3524-3530.
21. Zaki, P. A.; Keith, D. E., Jr.; Thomas, J. B.; Carroll, F. I.; Evans, C. J. Agonist-, antagonist-, and inverse agonist-regulated trafficking of the δ-opioid receptor correlates with, but does not require, G protein activation. J. Pharmacol. Exp. Ther. 2001, 298, 1015-1020.
22. Takemori, A. E.; Portoghese, P. S. Selective naltrexone-derived opioid receptor antagonists. Annu. Rev. Pharmacol. Toxicol. 1992, 32, 239-269.
23. Szmuszkovicz, J. U-50,488 and the kappa receptor: a personalized account covering the period 1973 to 1990. Prog. Drug. Res. 1999, 52, 167-195.
24. Costa, T.; Herz, A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 1989, 86, 7321-7325.
25. Costa, T.; Lang, J.; Gless, C.; Herz, A. Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol. Pharmacol. 1990, 37, 383-394.
26. Chiu, T. T.; Yung, L. Y.; Wong, Y. H. Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation. Mol. Pharmacol. 1996, 50, 1651-1657.
27. Mullaney, I.; Carr, I. C.; Milligan, G. Analysis of inverse agonism at the delta opioid receptor after expression in Rat 1 fibroblasts. Biochem. J. 1996, 315 (Pt 1), 227-234.
28. Merkouris, M.; Mullaney, I.; Georgoussi, Z.; Milligan, G. Regulation of spontaneous activity of the delta-opioid receptor: studies of inverse agonism in intact cells. J. Neurochem. 1997, 69, 2115-2122.
29. Hosohata, K.; Burkey, T. H.; Alfaro-Lopez, J.; Hruby, V. J.; Roeske, W. R.; Yamamura, H. I. (2S, 3R)TMT-L-Tic-OH is a potent inverse agonist at the human delta-opioid receptor. Eur. J. Pharmacol. 1999, 380, R9-R10.
30. Neilan, C. L.; Akil, H.; Woods, J. H.; Traynor, J. R. Constitutive activity of the delta-opioid receptor expresed in C6 glimoa cells: Identification of non-peptide delta-inverse agonists. Br. J. Pharmacol. 1999, 128, 556-562.
31. Chalmers, D. T.; Behan, D. P. The use of constitutively active GPCRs in drug discovery and functional genomics. Nat. Rev. Drug Discovery 2002, 1, 599-608.
32. Filliol, D.; Ghozland, S.; Chluba, J.; Martin, M.; Matthes, H. W.; Simonin, F.; Befort, K.; Gaveriaux-Ruff, C.; Dierich, A.; LeMeur, M.; Valverde, O.; Maldonado, R.; Kieffer, B. L. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 2000, 25, 195-200.
33. Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 1991, 258, 299-303.